Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
  2. Our UK Websites |
  3. Global Business Websites |
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  

Press Room

Contact us


One Onslow Street

Press enquiries only:

0845 372 6263


01483 505 515


01483 554 801


Content :

Sanofi Disappointed by Provisional NICE Decision Not To Approve Very Rare Disease Treatment Cerdelga® (eliglustat) For Use in the NHS

March 14, 2017

Eliglustat not recommended as a treatment option for adults with type 1 Gaucher disease in England, according to draft guidance


Sanofi and its specialty care global business unit, Sanofi Genzyme, are disappointed about the provisional recommendation by the National Institute of Health and Care Excellence (NICE) to not recommend eliglustat as a first-line oral treatment for adults with type 1 Gaucher disease in England. NICE published their draft guidance today in an Evaluation Consultation Document (ECD)1; this is not yet final guidance and may be subject to change.

“We are taking immediate action to better understand NICE’s position and the issues that led to this provisional recommendation.” said Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme. “Sanofi has gone to considerable effort to ensure this medicine benefits both patients and the NHS. Whilst today’s announcement is a disappointment, we are committed to working closely with NICE and the Gaucher community to allow eliglustat to become routinely available on the NHS for patients in England”.

Peter Kuiper added: “Although patients currently have access to existing therapies for the treatment of Gaucher disease, which have been supported by NHS commissioning for many years, eliglustat represents another step forward. At Sanofi Genzyme, we have been dedicated for more than 30 years to advancing the science behind Gaucher disease treatments and will in response to this ECD again submit our argument on why we believe this medicine represents good value for the NHS, based on both, how eliglustat works compared with existing treatments and the cost of treatment.”

As part of the HST submission to NICE, Sanofi proposed a simple patient access scheme that was accepted by the Department of Health. Patient access schemes allow manufacturers to subsidise the cost or discount the price the NHS pays for innovative medicines.

This is the first time NICE has evaluated the benefits and costs of using eliglustat within its licensed indication. Sanofi Genzyme will respond to publication of this ECD as part of the ongoing official consultation process.

Eliglustat was designated by the European Commission as an orphan medicine (a medicine used in rare diseases) on 4 December 2007 and was granted a marketing authorisation in the European Union on 19 January 2015.

For full prescribing information about eliglustat, the Summary of Product Characteristics can be found here: https://ec.europa.eu/health/documents/community-register/2015/20150119130463/anx_130463_en.pdf

The black triangle means this medicine is subject to additional monitoring. This will allow quick identification of new safety information. Side effects of medicines should be reported to your doctor or pharmacist.


1 The National Institute for Health and Care Excellence. Available at: https://www.nice.org.uk/guidance/indevelopment/gid-gaucherdiseasetype1eliglustatid709 . Last accessed March 2017

Date of preparation: March 2017 - Job bag number: GZUK.CERD.17.03.0123

Module :

Corporate Information

Corporate Information